Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

Glaucoma in perspective

- PMLiVE

Astellas selects new CFO for its EMEA operations

Japanesefirm also appoints newmanager for its US corporate affairs team

- PMLiVE

ViiV boosted by positive phase III results for HIV drug Triumeq

Data reaffirms benefitsof drug in comparison to current antiretroviral medications 

- PMLiVE

Proteus: Digital medicines set to transform healthcare

Tells PM Society event that pharma and health systems have reached a pivot point

- PMLiVE

FDA clears Taiho’s oral colorectal cancer drug

Regulatory nod for Lonsurf gives patients additional treatment options

- PMLiVE

DigitasLBi appoints Alvaro Cabrera as chief strategy officer

He joins the agency from OgilvyOneNew York

- PMLiVE

Roche says Esbriet boosts survival in pulmonary fibrosis

Positive results due to be presented at European Respiratory Society 

Is Technology Harming Your Brain?

Is technology harming your brain? Saycomms healthcare PR team confronts different opinions on how technology affects memories and attention span.

Say Communications

Machine-made humans: a spooky prospect

The healthcare team at Saycomms PR asks if major advances in 3D printing and bioprinting could lead to machine-made humans.

Say Communications

Gilead Sciences

Gilead reports positive data on ‘universal’ hepatitis C regimen

Sets sights on regulatory approval for combination therapy 

- PMLiVE

Bio investors react as Clinton tweet pledges pricing crackdown

Pharma companies come under scrutiny for pricing policies

- PMLiVE

Amgen granted priority review for extended use of Kyprolis

Trial data shows myeloma drug's improvement over Velcade

Shire Basingstoke

Shire wins EU approval for prolonged-release ADHD drug

First treatment in its class to be licensed for ADHD in Europe

Subscribe to our email news alerts

Latest content

Latest intelligence

Quick links